CJC-1295 no DAC + Ipamorelin5mg + 5mg

This set pairs CJC-1295 no DAC, a short-acting GHRH analog, with Ipamorelin, a selective growth-hormone secretagogue. The two ship as separate products and are not pre-mixed. They reach the pituitary through different receptors: CJC-1295 no DAC signals along the GHRH pathway, while Ipamorelin works through the ghrelin-receptor pathway. Research interest in combining them centers on that separation, since the two signals converge on the same growth-hormone-releasing cells from independent directions.

Because the pathways are distinct rather than overlapping, controlled studies of GHRH-plus-secretagogue pairings have generally reported a combined growth-hormone pulse greater than either compound produces on its own, though not every study has reproduced the effect. Research centers on growth-hormone and downstream IGF-1 signaling, with the short-acting GHRH component preserving a more pulse-style profile and the selective secretagogue adding a clean release without meaningfully raising cortisol or prolactin. It is commonly studied in growth-hormone-axis models and in recovery, sleep, and body-composition research.

Dedicated controlled data on this specific pairing remains limited, and much of the supporting evidence comes from earlier GHRH-and-secretagogue literature and from animal and laboratory work. That keeps both compounds investigational and distinct from approved therapies. Neither is FDA-approved.